The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

Get the detailed quarterly/annual income statement for RECURSION PHARMACEUTICALS INC (RXRX.MX). Find out the revenue, expenses and profit or loss over the last fiscal year.

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Researchers from MIT, Northeastern University, and Meta recently released a paper suggesting that large language models (LLMs) similar to those that power ChatGPT may sometimes prioritize sentence ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

In recent days, Recursion Pharmaceuticals announced a major leadership transition appointing Najat Khan, Ph.D., as CEO effective January 1, 2026, while also securing a milestone payment from Roche and ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...